Academic Journals Database
Disseminating quality controlled scientific knowledge

Clinical Investigation of Efficacy of Third-line and Beyond Pemetrexed Treatment in Advanced Non-squamous Non-small Cell Lung Cancer

ADD TO MY LIST
 
Author(s): Fei YU | Xiaoqing LIU | Xiaoyan LI | Jianjie LI | Wanfeng GUO | Haifeng QIN | Hongjun GAO

Journal: Chinese Journal of Lung Cancer
ISSN 1009-3419

Volume: 15;
Issue: 2;
Start page: 117;
Date: 2012;
Original page

Keywords: Pemetrexed | Lung neoplasms | Chemotherapy

ABSTRACT
Background and objective Pemetrexed in combination with platinum or a single-agent has been approved for the first- and second-line treatment of non-small cell lung cancer (NSCLC). However, the role of pemetrexed therapy in the third-line and beyond treatment of NSCLC has yet to be generally accepted. The present retrospective study reports the efficacy and safety of pemetrexed in the third-line and beyond treatment of advanced non-squamous NSCLC. Methods A total of 46 patients with advanced non-squamous NSCLC received a combination of pemetrexed plus platinum or a single-agent after multi-line treatment failed to yield positive results. Results Of the 46 patients who participated in the study, 7 achieved partial responses, 20 reached a stage of stable disease, and 19 reached a stage of progressive disease. The over-all object response rate was 15.2% and the disease control rate (DCR) was 58.7%. The median progression-free survival time was 3.0 months. Pemetrexed in combination with platinum yielded a higher DCR than the pemetrexed plus single-agent treatment (P=0.043). Common adverse events included nausea, vomiting and myelosuppression. Conclusion Administration of pemetrexed after failure of multi-line treatment is clinically beneficial to patients with advanced non-squamous NSCLC. The toxic effects of the treatment appear to be tolerable.
Why do you need a reservation system?      Affiliate Program